Table 3. Aliskiren/amlodipine combination therapy versus amlodipine monotherapy on adverse events.

Category	RR	95% CI	p-value
Any AEs	1.02	0.95–1.10	0.56
Dicontinuation due to AEs	0.64	0.50–0.83	0.0008
Any SAEs	0.71	0.34–1.47	0.36
Peripheral edema	0.78	0.66–0.92	0.004
Nasopharyngitis	1.09	0.67–1.78	0.73
Dizziness	1.17	0.75–1.84	0.48
Headache	0.76	0.48–1.22	0.25
Hyperkalaemia	0.77	0.40–1.47	0.42
Hypokalaemia	0.51	0.27–0.97	0.04

Abbreviations: RR, relative risk; CI, confidence interval; AEs, adverse events; SAEs, serious adverse events.